| Literature DB >> 32621136 |
Thomas Peros1, Joost van Schuppen2, Anneloes Bohte3, Caspar Hodiamont4, Eleonora Aronica5, Timo de Haan6.
Abstract
Central nervous system (CNS) infections are potentially life threatening in neonates and can lead to the ill-defined diagnosis of ventriculitis. With this study we aimed to explore and describe ventriculitis regarding clinical, microbiological and ultrasonographic characteristics. We performed a retrospective cohort study including all neonates with a culture-proven CNS infection admitted to our tertiary NICU over a 12-year period (2004-2016). For each case clinical data was gathered, and three timed cranial ultrasounds were anonymized and retrospectively reviewed and assessed for signs of ventriculitis. Forty-five patients were included with 9 (20%) diagnosed with ventriculitis. Mortality in both ventriculitis and non-ventriculitis cases was one-third. Patients with pre-existing conditions as post-haemorrhagic hydrocephalus are at risk of developing ventriculitis. Most common pathogens were gram negative bacteria (68.9%). Ultrasonographic signs of ventriculitis developed over time, and interrater agreement was substantial.Entities:
Keywords: CNS infections; Cranial ultrasound; Meningitis; Neonate; Ventriculitis
Mesh:
Substances:
Year: 2020 PMID: 32621136 PMCID: PMC7666663 DOI: 10.1007/s00431-020-03723-3
Source DB: PubMed Journal: Eur J Pediatr ISSN: 0340-6199 Impact factor: 3.183
Patient characteristics, comorbidities, symptoms and illness severity
| Meningitis ( | Ventriculitis ( | All ( | |||
|---|---|---|---|---|---|
| Patient characteristics | |||||
| Gestational age | 1 | 28.0 (24.7–40.7) | 27.4 (25.4–30.0) | 28.0 (24.7–40.7) | |
| Birth weight (grams) | 1 | 1110 (585–4690) | 895 (725–1570) | 1090 (585–4690) | – |
| Male | 21 (58.3%) | 4 (44.4%) | 25 (55.6%) | – | |
| Twin | 5 (13.8%) | 1 (11.1%) | 6 (13.3%) | – | |
| APGAR < 5 at 5 min | 4 (11.1%) | 1 (11.1%) | 5 (11.1%) | – | |
| Birth defects | 3 (8.3%) | 0 (0%) | 3 (6.7%) | – | |
| Antibiotics after birth in days | 1 | 2 (0–14) | 3 (1–7) | 2 (0–14) | – |
| No antenatal steroids | 10 (27.7%) | 2 (22.2%) | 12 (26.7%) | – | |
| Diagnosis and pre-existing comorbidities | |||||
| Weight at diagnosis | 1 | 1090 (650–4380) | 1010 (870–2360) | 1080 (650–4380) | – |
| Age (days) at diagnosis | 4 | 11.8 (± 9.4) | 34.7 (± 32.1) | 16.4 (± 18.5) | – |
| CVL > 1 day at diagnosis | 2 | 23 (63.8%) | 2 (22.2%) | 25 (55.6%) | 0.030 |
| PDA | 2 | 8 (22.2%) | 6 (66.6%) | 14 (31.1%) | 0.002 |
| PDA requiring treatment | 2 | 5 (13.8%) | 4 (44.4%) | 9 (20%) | – |
| Surgical comorbidity (including NEC) | 10 (27.7%) | 3 (33.3%) | 13 (28.9%) | – | |
| Prolonged respiratory support | 6 (16.6%) | 3 (33.3%) | 9 (20%) | – | |
| Fully TPN dependant | 7 (19.4%) | 1 (11.1%) | 8 (17.8%) | – | |
| PHVD requiring drainage | 2 | 2 (5.55%) | 4 (44.4%) | 6 (13.3%) | 0.010 |
| Symptoms at diagnosis | |||||
| Apneas/bradycardia | 21 (58.3%) | 2 (22.2%) | 23 (51.1%) | – | |
| Neurological symptoms | 2 (5.5%) | 1 (11.1%) | 3 (6.7%) | – | |
| GI symptoms | 6 (16.6%) | 1 (11.1%) | 7 (15.6%) | – | |
| Circulatory failure | 16 (44.4%) | 2 (22.2%) | 18 (40%) | – | |
| Respiratory failure | 20 (55.5%) | 4 (44.4%) | 24 (53.3%) | – | |
| Skin lesions | 3 (8.33%) | 0 (0%) | 3 (6.7%) | – | |
| Fever | 1 (2.7%) | 1 (11.1%) | 2 (4.4%) | – | |
| Support required | |||||
| Non-invasive respiratory support | 3 | 7 (19.4%) | 2 (22.2%) | 9 (20%) | – |
| Invasive ventilation | 3 | 25 (69.4%) | 5 (55.5%) | 30 (66.7%) | – |
| Fluid resuscitation | 3 | 8 (22.2%) | 3 (33.3%) | 11 (24.4%) | – |
| Inotropic support | 3 | 16 (44.4%) | 2 (22.2%) | 18 (40%) | – |
| Post diagnosis complications | |||||
| Hydrocephalus (requiring treatment) | 2 | 1 (2.77%) | 5 (55.5%) | 6 (13.3%) | 0.001 |
| Seizures | 2 | 6 (16/6%) | 4 (44.4%) | 10 (22.2%) | 0.017 |
| Cerebral abscess | 2 | 1 (2.77%) | 2 (22.2%) | 3 (6.7%) | – |
| Death | 12 (33.3%) | 3 (33.3%) | 15 (33.3%) | – | |
| Laboratory results | |||||
| CRP (mg/l) | 1 | 47.3 (0–265.1) | 69.2 (0–260.8) | 49.3 (0–265.1) | – |
| Platelets (× 10e9/L) | 1 | 130 (0–534) | 125 (30–403) | 128 (0–534) | – |
| WBC (× 10e9/L) | 1 | 13 (1.5–42.1) | 11.1 (5.3–29.4) | 13 (1.5–42.1) | – |
| CSF WBC (× 10e6/L) | 1 | 102 (1–51.200) | 1376 (141–43.410) | 144 (1–51.200) | – |
| CSF protein (g/L) | 2, 4 | 1.98 (± 1.33) | 3.58 (± 2.72) | 2.23 (± 1.67) | 0.029 |
| CSF glucose (mmol/l) | 2, 4 | 3.68 (± 2.29) | 1.13 (± 1.08) | 3.43 (± 2.32) | 0.009 |
| CSF WBC polymorphonuclear % | 4 | 47.4% (± 20.8%) | 68.7% (± 4.3%) | 51.0% (± 20.8%) | – |
| CSF WBC mononuclear % | 4 | 52.6% (± 20.9%) | 31.3% (± 4.3% | 49.0% (± 20.8%) | – |
1, Values are medians and range. 2, Significant difference between meningitis and ventriculitis. 3, Support required any time after onset of illness. 4, Values are mean and standard deviation
Pathogens
| Meningitis | Ventriculitis | All | ||||
|---|---|---|---|---|---|---|
| ( | ( | ( | ||||
| % | % | % | ||||
| Coagulase negative staphylococci | 3 | 8.3% | 2 | 22.2% | 5 | 11.1% |
| 4 | 11.1% | 0 | 0.0% | 4 | 8.9% | |
| Group B streptococcus | 3 | 8.3% | 0 | 0.0% | 3 | 6.7% |
| 1 | 2.8% | 1 | 11.1% | 2 | 4.4% | |
| 30.6% | 33.3% | |||||
| 7 | 19.4% | 3 | 33.3% | 10 | 22.2% | |
| 7 | 19.4% | 1 | 11.1% | 8 | 17.8% | |
| 4 | 11.1% | 2 | 22.2% | 6 | 13.3% | |
| 4 | 11.1% | 0 | 0.0% | 4 | 8.9% | |
| 2 | 5.6% | 0 | 0.0% | 2 | 4.4% | |
| 1 | 2.8% | 0 | 0.0% | 1 | 2.2% | |
| 69.4% | 66.7% | |||||
No significant difference between meningitis and ventriculitis groups
Ultrasound findings and time course
| CUS1 ( | CUS2 ( | CUS3 ( | Sign (1–2) | Sign (2–3) | |
|---|---|---|---|---|---|
| Abnormal CSF (ventricular) ± | 5% (2) | 15% (6) | 26% (8) | 0.030* | 0.000* |
| Abnormal CSF (peripheral) ± | 5% (2) | 10% (4) | 13% (4) | 0.000* | 0.042* |
| Abnormal ventricular lining ± | 5% (2) | 10% (4) | 16% (5) | 0.504 | 0.028* |
| Hydrocephalus | 8% (3) | 15 (6) | 26% (8) | 0.002* | 0.063 |
| IVH | 85% (33) | 73% (30) | 77% (24) | 0.120 | 0.218 |
| Flaring | 15% (6) | 15% (6) | 0% (0) | 0.331 | 0.315 |
| Parenchymal focal/diffuse | 0% (0) | 7% (3) | 10% (3) | 0.057 | 0.562 |
| Echogenic lining of gyri | 10% (4) | 7% (3) | 3% (1) | 0.220 | 0.234 |
| Abnormal shape of gyration | 15% (6) | 17% (7) | 13% (4) | 0.423 | 0.127 |
| Other: Ischaemia | 0% (0) | 7% (3) | 6% (2) | 0.209 | 0.004* |
| Other: Infarction | 3% (1) | 7% (3) | 0% (0) | 0.489 | 0.000* |
| Other: Increased RI | 8% (3) | 17 (7) | 26% (8) | 0.257 | 0.168 |
| Other: Oedema | 0% (0) | 0% (0) | 3% (1) | 0.197 | 0.245 |
| Other: Abscess | 0% (0) | 2% (1) | 3% (1) | 0.288 | 0.149 |
±Diagnostic criteria for ventriculitis
CUS1, baseline; CUS2 at diagnosis, CUS3 1 week post diagnosis
Sign (1–2): p value of Pearson Chi-square comparing difference between CUS1 and CUS2 finding
Sign (2–3): p value of Pearson Chi-square comparing difference between CUS2 and CUS3 finding
*Indication of significance
Fig. 1Ultrasound imaging from our cohort. (I) Top row shows images from ventriculitis patients. (II) Bottom row shows contrasting images from meningitis patients. IA: Slightly thickened ultrasound rich ventricle walls. IB: Coronal image of bilateral enlarged ventricles, with stranding in the right ventricle. IC: Coronal image showing hyperechoic lining of the gyri and sulci, hyperechoic peripheral CSF. ID: Hyperechoic appearance of white matter. IIA: Normal periventricular lining. IIB: Normal non-reflecting CSF. No hydrocephalus. IIC: Virtual normal lining. IID: Normal white matter surrounding the ventricles